Compare · HUM vs VRDN
HUM vs VRDN
Side-by-side comparison of Humana Inc. (HUM) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.80B, about 17.1x VRDN ($2.74B).
- Both names hit the wire about 6 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Humana Inc.
- Viridian Therapeutics Inc.
- Price
- $388.85+0.65%
- $24.20+0.79%
- Market cap
- $46.80B
- $2.74B
- 1M return
- +2.03%
- -
- 1Y return
- +30.12%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 25
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Latest HUM
- Humana Names Dr. Shantanu Nundy as Chief Medical Officer
- James P. Holland to Join Humana as Medicaid President
- Humana upgraded by Morgan Stanley with a new price target
- Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
- Director Smith Paul John was granted 544 units of Humana Common (SEC Form 4)
- Director Crawford Frederick John was granted 544 units of Humana Common (SEC Form 4)
- Humana upgraded by Evercore ISI with a new price target
- Humana upgraded by Leerink Partners with a new price target
- Humana downgraded by Raymond James
- New insider Crawford Frederick John claimed ownership of 21 units of Humana Common (SEC Form 3)
Latest VRDN
- Chief Legal Officer Tousignant Jennifer sold $348,194 worth of shares (14,212 units at $24.50) and exercised 10,000 shares at a strike of $14.41, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Tripuraneni Radhika exercised 40,000 shares at a strike of $13.21 (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Viridian Therapeutics Inc.
- SEC Form 10-Q filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
- SEC Form 4 filed by Director Morris Arlene
- SEC Form 4 filed by Director Kiselak Tomas
- SEC Form 4 filed by Director Gheuens Sarah
- SEC Form 4 filed by Director Moses Jennifer K.